CD8A and neoplasm: Interestingly, use of CD200fc, which is an CD200R1 agonist, significantly decreased the growth of metastatic breast cancer 4THM cells due to the inhibition of cancer-related inflammation and increase both the tumor-infiltrating CD8+ T cell number and tumor-induced IFN-γ secretion [95].